Sikkim Journal

Peripheral Arterial Disease Market, Epidemiology & Market Forecast -2030

 Breaking News
  • No posts were found

Peripheral Arterial Disease Market, Epidemiology & Market Forecast -2030

September 01
12:28 2021
Peripheral Arterial Disease Market, Epidemiology & Market Forecast -2030
DelveInsight Business Research LLP
DelveInsight’s “Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Market“ report delivers an in-depth understanding of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD), historical and forecasted epidemiology as well as the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Peripheral Arterial Disease Market

The Peripheral Arterial Disease market report provides current treatment practices, emerging drugs, Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) market share of the individual therapies, current and forecasted Pulmonary Vascular Disease market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Pulmonary Vascular Disease treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Market Outlook

The Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) market in 7MM is expected to change in the study period 2017-2030.

Request for sample pages @ Peripheral Arterial Disease Market Forecast 

Table of contents

. Key Insights

2. Executive Summary of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)

3. Competitive Intelligence Analysis for Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)

4. Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD): Market Overview at a Glance

4.1. Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Total Market Share (%) Distribution in 2017

4.2. Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Total Market Share (%) Distribution in 2030

5. Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD): Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms

5.3. Pathophysiology

5.4. Risk Factors

5.5. Diagnosis

6. Patient Journey

7. Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Treatment and Management

8.2. Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD): Seven Major Market Analysis

13.1. Key Findings

13.2. Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Market Size in 7MM

13.3. Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Total Market Size in the United States

15.1.2. Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Total Market Size in Germany

15.3.2. Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Total Market Size in France

15.4.2. Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Total Market Size in Italy

15.5.2. Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Total Market Size in Spain

15.6.2. Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Total Market Size in the United Kingdom

15.7.2. Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Total Market Size in Japan

15.8.3. Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

*The table of contents is not exhaustive; the final content may vary. 

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/